系统的文献综述和专家意见使用粘质酸补充透明质酸在不同部位的骨关节炎。

IF 1.7 Q2 ORTHOPEDICS
Orthopedic Research and Reviews Pub Date : 2021-12-02 eCollection Date: 2021-01-01 DOI:10.2147/ORR.S336185
Alberto Migliore, Gianfranco Gigliucci, Lyudmila Alekseeva, Raveendhara R Bannuru, Tomasz Blicharski, Demirhan Diracoglu, Athanasios Georgiadis, Hesham Hamoud, Natalia Martusevich, Marco Matucci Cerinic, Jan Perduk, Imre Szerb, Tomáš Trč, Xavier Chevalier
{"title":"系统的文献综述和专家意见使用粘质酸补充透明质酸在不同部位的骨关节炎。","authors":"Alberto Migliore,&nbsp;Gianfranco Gigliucci,&nbsp;Lyudmila Alekseeva,&nbsp;Raveendhara R Bannuru,&nbsp;Tomasz Blicharski,&nbsp;Demirhan Diracoglu,&nbsp;Athanasios Georgiadis,&nbsp;Hesham Hamoud,&nbsp;Natalia Martusevich,&nbsp;Marco Matucci Cerinic,&nbsp;Jan Perduk,&nbsp;Imre Szerb,&nbsp;Tomáš Trč,&nbsp;Xavier Chevalier","doi":"10.2147/ORR.S336185","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial<sup>®</sup> [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.</p>","PeriodicalId":19608,"journal":{"name":"Orthopedic Research and Reviews","volume":"13 ","pages":"255-273"},"PeriodicalIF":1.7000,"publicationDate":"2021-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/cc/orr-13-255.PMC8648269.pdf","citationCount":"13","resultStr":"{\"title\":\"Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis.\",\"authors\":\"Alberto Migliore,&nbsp;Gianfranco Gigliucci,&nbsp;Lyudmila Alekseeva,&nbsp;Raveendhara R Bannuru,&nbsp;Tomasz Blicharski,&nbsp;Demirhan Diracoglu,&nbsp;Athanasios Georgiadis,&nbsp;Hesham Hamoud,&nbsp;Natalia Martusevich,&nbsp;Marco Matucci Cerinic,&nbsp;Jan Perduk,&nbsp;Imre Szerb,&nbsp;Tomáš Trč,&nbsp;Xavier Chevalier\",\"doi\":\"10.2147/ORR.S336185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial<sup>®</sup> [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.</p>\",\"PeriodicalId\":19608,\"journal\":{\"name\":\"Orthopedic Research and Reviews\",\"volume\":\"13 \",\"pages\":\"255-273\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/cc/orr-13-255.PMC8648269.pdf\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orthopedic Research and Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ORR.S336185\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopedic Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ORR.S336185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 13

摘要

骨关节炎(OA)是导致残疾的重要原因。考虑到透明质酸(HA)粘质补充剂(VS)的日益普及,国际关节内治疗研讨会(ISIAT)任命了一个技术专家小组(TEP)来确定OA中特定HA成功VS的标准;这是通过系统文献综述(SLR),按照PRISMA指南进行,询问Medline、Embase、Cochrane图书馆、护理和相关健康文献累积索引(CINAHL)、Grey Matters和美国风湿病学会(ACR/EULAR)数据库以及国际专家的意见。这项研究只包括对成年人和人类的研究,没有语言和发表时间的限制。研究人员从每项研究中提取定量和定性数据。采用混合方法评价工具(MMAT)对证据水平进行质量分析。SLR检索到385篇论文,其中25篇适合分析。TEP集中于产品Sinovial®的不同配方[HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]。这一选择是由于有大量可用的证据。TEP在两轮德尔菲调查中权衡了证据;结果和任何分歧都是在最后一次会议上讨论的。考虑三个领域:1)与最佳结果相关的患者特征;2)与失败风险增加相关的禁忌症和情况;3)认为VS合适的临床条件。TEP的结论是,HA联合VS治疗I至III级膝关节和髋关节OA是安全有效的,并且在其他情况下也可以进行VS(例如IV级kellgreen - lawrence - KL);手术前应对病人进行全面检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis.

Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis.

Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial® [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Orthopedic Research and Reviews
Orthopedic Research and Reviews Medicine-Orthopedics and Sports Medicine
CiteScore
2.80
自引率
0.00%
发文量
51
审稿时长
16 weeks
期刊介绍: Orthopedic Research and Reviews is an international, peer-reviewed, open-access journal focusing on the patho-physiology of the musculoskeletal system, trauma, surgery and other corrective interventions to restore mobility and function. Advances in new technologies, materials, techniques and pharmacological agents will be particularly welcome. Specific topics covered in the journal include: Patho-physiology and bioengineering, Technologies and materials science, Surgical techniques, including robotics, Trauma management and care, Treatment including pharmacological and non-pharmacological, Rehabilitation and Multidisciplinarian care approaches, Patient quality of life, satisfaction and preference, Health economic evaluations. The journal welcomes submitted papers covering original research, basic science and technology, clinical studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信